Literature DB >> 1795005

The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.

J A Radford1, J M Margison, R Swindell, M J Lind, P M Wilkinson, N Thatcher.   

Abstract

Dose fractionation is known to reduce the toxicity of ifosfamide and also results in an increased production of alkylating metabolites. Administration by slow infusion using the convenience of ambulatory pumps is therefore of interest. We used HPLC to investigate the stability of ifosfamide in aqueous solution (either alone, solution A, or mixed with mesna, solution B) under various conditions over a 9-day period. At both ambient temperature in daylight and 27 degrees C in a dark environment, there was no evidence of ifosfamide decay in either solution. However, at 37 degrees C in a dark environment, a fall was detected in both solutions, which at 9 days amounted to a loss of 7% of the amount of ifosfamide present at time zero. At 70 degrees C, levels of ifosfamide in both solutions fell within 72 h to markedly lower levels than controls, thus confirming that the methods used were indicative of stability. We conclude that ifosfamide, either alone or mixed with mesna, is stable for 9 days at temperatures up to 27 degrees C; even at 37 degrees C, the measured loss is small. The continuous infusion of ifosfamide over 7 days by ambulatory pump is now a practical proposition.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1795005     DOI: 10.1007/BF01613222

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  6 in total

Review 1.  Ifosfamide--pharmacology, safety and therapeutic potential.

Authors:  W P Brade; K Herdrich; M Varini
Journal:  Cancer Treat Rev       Date:  1985-03       Impact factor: 12.111

2.  Infusion of ifosphamide plus mesna.

Authors:  I C Shaw; J W Rose
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

3.  Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Cancer Res       Date:  1989-02-01       Impact factor: 12.701

4.  Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.

Authors:  L R Morgan; E F Harrison; J E Hawke; H L Hunter; J J Costanzi; D Plotkin; W G Tucker; P M Worrall
Journal:  Semin Oncol       Date:  1982-12       Impact factor: 4.929

5.  A simple quantitative HPLC assay for ifosfamide in biological fluids.

Authors:  J M Margison; P M Wilkinson; T Cerny; N Thatcher
Journal:  Biomed Chromatogr       Date:  1986-06       Impact factor: 1.902

6.  Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.

Authors:  B M Bryant; M Jarman; H T Ford; I E Smith
Journal:  Lancet       Date:  1980-09-27       Impact factor: 79.321

  6 in total
  3 in total

1.  Targeted Therapy of Ewing's Sarcoma.

Authors:  Vivek Subbiah; Pete Anderson
Journal:  Sarcoma       Date:  2010-10-31

Review 2.  A review of the use of chemoprotectants in cancer chemotherapy.

Authors:  C Lewis
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

3.  Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma.

Authors:  Juan Martin-Liberal; Salma Alam; Anastasia Constantinidou; Cyril Fisher; Komel Khabra; Christina Messiou; David Olmos; Scott Mitchell; Omar Al-Muderis; Aisha Miah; Mark Linch; Robin L Jones; Michelle Scurr; Ian Judson; Charlotte Benson
Journal:  Sarcoma       Date:  2013-12-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.